This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie (ABBV) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 2.91% and 1.83%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Q3 Earnings Top, Prolia, Biosimilars Drive Sales
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for both earnings and sales. It slightly narrows its previously issued sales guidance for 2020 while raising its earnings range.
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q3 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.
Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.
AbbVie (ABBV) Stock Moves -0.5%: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $83.92, marking a -0.5% move from the previous day.
Will AbbVie (ABBV) Q3 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Investors will focus on any recovery in AbbVie's (ABBV) sales amid the coronavirus pandemic when it reports third-quarter results.
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Aclaris (ACRS) Begins Phase II Study on Eczema Candidate
by Zacks Equity Research
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $84.25, marking a -0.07% move from the previous day.
ImmunoGen (IMGN) Inks Mirvetuximab Development Deal in China
by Zacks Equity Research
ImmunoGen (IMGN) grants exclusive rights to Huadong Medicine for development and commercialization of mirvetuximab soravtansine in Greater China.
AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Rinvoq ??? atopic dermatitis. The drug is already marketed to treat rheumatoid arthritis.
Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients
by Zacks Equity Research
Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.
Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod
by Zacks Equity Research
Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec
by Zacks Equity Research
Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
AbbVie (ABBV) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $87.83 in the latest trading session, marking a -0.55% move from the prior day.
Gilead & Galapagos Announce Positive Data on UC Candidate
by Zacks Equity Research
Gilead (GILD) and partner Galapagos report positive data on filgotinib for the indication of active ulcerative colitis.
Lilly's Mirikizumab Retains Efficacy in Crohn's Disease Study
by Zacks Equity Research
Eli Lilly's (LLY) mirikizumab continues to show symptom improvement and reduction of intestinal mucosal inflammation in Crohn's disease patients after a year-long treatment in a mid-stage study.
J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats third-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.
Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote
by Zacks Equity Research
Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.
Top Research Reports for Visa, Walmart & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Walmart (WMT) and Abbott Laboratories (ABT).